All In Biotech

Drug Trial Radar · NCT06987058

RVU120 Rollover Study

An Open-label Multicenter Rollover Study to Provide Continued Treatment to Participants Previously Enrolled in a RVU120 Clinical Study

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

14

Planned (sponsor's estimate)

Start

Dec 4, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Ryvu Therapeutics SAIndustry
Sponsor type
Industry
First posted
May 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when continued under the same regimen as in the parent study. To be eligible for this rollover study, participants must be continuing to benefit from their treatment, show an acceptable safety profile, and not have access to commercially available comparator anticancer therapy. Once transitioned to this study, participants will continue with their next planned dose per the regimen of their parent study.

Conditions

  • Advanced Solid Tumors
  • Acute Myeloid Leukaemia (AML)
  • High-risk Myelodysplastic Syndrome

Interventions

  • RVU120Drug

    RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19

  • RuxolitinibDrug

    Selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (Safety and Tolerability)Time frame: 12 months

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Hôpital l'Archet 1 - CHU de Nice; Service Hématologie Clinique

    Nice, France

  • Hôpital Haut-Lévêque- CHU de Bordeaux, Centre François Magendie, Service d'Hématologie Clinique et Thérapie Cellulaire

    Pessac, France

  • M2M Med Sp. Z o.o.

    Chorzów, Poland

  • CWBK UCK Ośrodek Badań Klinicznych Wczesnych Faz

    Gdansk, Poland

  • Pratia Hematologia Sp. z o.o. Pratia Onkologia Katowice

    Katowice, Poland

  • SPZOZ Szpital Uniwersytecki w Krakowie

    Krakow, Poland

  • Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Terapii Komórkowych i Chorób Wewnętrznych

    Wroclaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.